Literature DB >> 9141290

Medical marijuana and its use by the immunocompromised.

J M McPartland1, P L Pruitt.   

Abstract

BACKGROUND: Those immunocompromised by AIDS or cancer chemotherapy use marijuana to allay symptoms of their disease or treatment. Some researchers believe that marijuana may further suppress the immune system. A list of immunological hazards that may be present in marijuana was collated and assessed, and clinical recommendations regarding the use of marijuana by immunocompromised individuals were made.
METHODS: Databases and other sources from 1964 to 1996 were searched using keywords (e.g., cannabinoids, cannabis, hemp, marijuana). This was supplemented by a manual search of bibliographies, nonindexed books, and journals, and by consultation with experts. All reports were analyzed for antecedent sources. Data validity was assessed by source, identification methodology, and frequency of independent observations.
RESULTS: Substances implicated as potential immunological hazards in marijuana include endogenous constituents (cannabinoids, pyrolyzed gases, and particulates) and a longer list of exogenous contaminants, both natural (fungi and their metabolites) and synthetic (pesticides and adulterants).
CONCLUSION: Burning of marijuana creates toxins of combustion. Particulate toxins (tars) are reduced by the use of vaporizer apparati. Gas-phase toxins are filtered by water pipes, but water pipes also filter some tetrahydrocannabinol, making this strategy counterproductive. Viable fungal spores in marijuana pose the greatest hazard to immunocompromised patients, though they can be sterilized by several methods. Pesticide residues and other adulterants may be present in black-market marijuana, but are absent in sources of marijuana that are approved by the Food and Drug Administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141290

Source DB:  PubMed          Journal:  Altern Ther Health Med        ISSN: 1078-6791            Impact factor:   1.305


  10 in total

1.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

2.  Low-dose vaporized cannabis significantly improves neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Reena Deutsch; Ben Gouaux; Staci Sakai; Haylee Donaghe
Journal:  J Pain       Date:  2012-12-11       Impact factor: 5.820

3.  Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence.

Authors:  Raul Gonzalez; Randi M Schuster; Jasmin Vassileva; Eileen M Martin
Journal:  J Clin Exp Neuropsychol       Date:  2011-06-24       Impact factor: 2.475

Review 4.  Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence.

Authors:  Rishabh Verma; Farazul Hoda; Mawrah Arshad; Asif Iqubal; Ali Nasir Siddiqui; Mohammad Ahmed Khan; Syed Ehtaishamul Haque; Mohd Akhtar; Abul Kalam Najmi
Journal:  Med Cannabis Cannabinoids       Date:  2021-05-21

Review 5.  Cannabis and the liver: Things you wanted to know but were afraid to ask.

Authors:  Julie Zhu; Kevork M Peltekian
Journal:  Can Liver J       Date:  2019-08-27

Review 6.  Medical marijuana: medical necessity versus political agenda.

Authors:  Peter A Clark; Kevin Capuzzi; Cameron Fick
Journal:  Med Sci Monit       Date:  2011-12

Review 7.  Systematic reviews of complementary therapies - an annotated bibliography. Part 2: herbal medicine.

Authors:  K Linde; G ter Riet; M Hondras; A Vickers; R Saller; D Melchart
Journal:  BMC Complement Altern Med       Date:  2001-07-20       Impact factor: 3.659

8.  Determination of pesticide residues in cannabis smoke.

Authors:  Nicholas Sullivan; Sytze Elzinga; Jeffrey C Raber
Journal:  J Toxicol       Date:  2013-05-12

Review 9.  Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

Authors:  John M McPartland; Geoffrey W Guy; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 10.  The nephrologist's guide to cannabis and cannabinoids.

Authors:  Joshua L Rein
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.